Samsung Biologics

Historical price data

Samsung Biologics has established itself as a leading global CDMO in the biologics space, leveraging Samsung Group's technological expertise and manufacturing excellence. The company has invested heavily in expanding its biomanufacturing capacity and capabilities, making it one of the largest contract manufacturers worldwide. With a strong track record of regulatory approvals and successful product launches, Samsung Biologics continues to attract major pharmaceutical partners seeking reliable, large-scale biologics production. The company's strategic focus on innovation, quality, and capacity expansion positions it well for continued growth in the rapidly expanding biologics market.

Comprehensive biologics CDMO platform providing end-to-end services from cell line development to commercial manufacturing, with over 620,000L of total bioreactor capacity across multiple state-of-the-art facilities.

Total raised: $2B

Samsung Biologics competes with major CDMOs including Lonza, WuXi Biologics, and Catalent but differentiates through its massive scale, Samsung Group backing, and strategic Asian location. The company's focus on quality and regulatory excellence has established it as a preferred partner for global pharmaceutical companies.